Monitoring report · published · reflects the rules at that date

Request for a Scientific Opinion on Heliotropin

Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.

See what happens after launch

What’s new?

On 26 June 2025, the Scientific Committee on Consumer Safety (SCCS) approved a new mandate to evaluate the safety of Heliotropin (CAS No. 120-57-0, EC No. 204-409-7), also known as piperonal, in cosmetic products.

This assessment was formally requested by the European Commission following receipt of an industry dossier in June 2025 defending the safe use of Heliotropin as a fragrance ingredient under Article 15(2) of the Cosmetics Regulation (EC) No 1223/2009.

The mandate was triggered by the European Risk Assessment Committee (RAC) opinion issued in September 2024 recommending classification of Heliotropin as ‘Reproductive toxicant Category 1B (H360Fd)’ under the CLP Regulation. This classification, if implemented, would normally result in a prohibition of use in cosmetic products under Article 15(2) of the EU Cosmetics Regulation, unless specific safety criteria can be demonstrated.

Heliotropin is currently not listed in any Annex of the EU Cosmetics Regulation and has been widely used as a fragrance ingredient in perfumes, lotions, creams, shampoos, and other cosmetic products for its characteristic sweet, floral scent with vanilla and almond notes.

What now?

The SCCS is specifically requested to address the following issues:

  • Whether Heliotropin is safe when used as an ingredient in fine fragrances for adults only up to 1.8% concentration
  • If 1.8% is not considered safe, what maximum concentration would be acceptable for Heliotropin in cosmetic products
  • Identification of any further scientific concerns regarding Heliotropin use in cosmetic products beyond reproductive toxicity
  • Assessment of dermal, inhalation, and oral exposure risks from typical cosmetic use patterns

Preliminary opinion expected within 9 months following standard SCCS evaluation procedures, with public consultation period.

References

European Commission, Request for a scientific Opinion on the safety of Heliotropin (CAS No. 120-57-0, EC No. 204-409-7), SCCS mandate approved 26 June 2025, published 27 June 2025.

Need to know what this means for a product you have on the market now?

Ask the team for this area

One question works best. Leave out confidential product details; we can take those up by email.

Our team replies to every question. The reply goes to the email you gave.

We use your email to answer this question and for nothing else. Privacy and cookies

Follow an area

One email when an area publishes, in the language you choose. Nothing else.

Talk to us

Tell us the product, the market and the date you are working to. If the date is not realistic, we will say so.

Need a standing regulatory partner? See ongoing support →